Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000803280 | SCV000943143 | pathogenic | Ataxia-telangiectasia syndrome | 2019-02-04 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 2-4 of the ATM gene, which includes the initiator codon. The 5' end of this event is unknown as it extends beyond the assayed region for this gene and therefore may encompass additional genes. The 3' boundary is likely confined to intron 4 of the ATM gene. This is expected to result in an absent or disrupted protein product. Similar deletion of exons 2-4 has not been reported in the literature in individuals with ATM-related disease. However, a deletion of exons 2-3 (also known as exons 1-2 in the literature), which removes the initiator codon in exon 2, has been observed in individuals affected with breast cancer (PMID: 28486781). Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). For these reasons, this variant has been classified as Pathogenic. |